Stockwinners Market Radar for September 26, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:24 EDT HF Sinclair exec sells $2.84M in common stock - In a regulatory filing, HF Sinclair disclosed that its EVP Michael Jennings sold 50K shares of common stock on September 26th in a total transaction size of $2.84M.

20:12 EDT Cathie Wood's ARK Investment bought 58.3K shares of Markforged today

19:45 EDT Medalist Diversified REIT CEO buys $58.2K in common stock - In a regulatory filing, Medalist Diversified REIT disclosed that its CEO Frank Kavanaugh bought 2.5K shares of common stock on September 22nd in a total transaction size of $58.2K.

18:04 EDT NextEra to sell Florida City Gas to Chesapeake for $923M in cash - NextEra Energy (NEE) announced its Florida Power & Light Company subsidiary has entered into a definitive agreement to sell Florida City Gas to Chesapeake Utilities Corporation (CPK) for $923M in cash. "We are pleased that FPL has reached this agreement to sell FCG to Chesapeake Utilities," said John Ketchum, chairman, president and chief executive officer, NextEra Energy. "This transaction allows us to continue our strategy of redeploying capital into our core businesses. I want to thank the FCG team for their hard work and accomplishments and am confident they will continue to be successful in the years to come." The transaction value of $923M, including $145M of intercompany debt, is expected to be accretive to NextEra Energy earnings immediately upon closing. The impact of the gain on sale at the time of closing will be excluded from adjusted earnings. Expected to be completed over the next several months, the sale is conditioned upon satisfaction of the Hart-Scott-Rodino review and customary closing conditions.

17:58 EDT BioMarin receives FDA orphan designation for HCM treatment - According to a post on the FDA's website, BioMarin receives orphan designation for its treatment of patients with hypertrophic cardiomyopathy with a mutation in the MYBPC3 gene. Reference Link

17:38 EDT Athena Consumer Acquisition to delist upon combination with Next.e.GO Mobile - Athena Consumer Acquisition announced that, upon the consummation of its previously announced proposed business combination with Next.e.GO Mobile, it intends to voluntarily delist its Class A common stock, units and public warrants from the NYSE American, subject to the satisfaction or waiver, as applicable, of all closing conditions in connection with the Business Combination. The Company's Class A common stock, units and public warrants will continue to trade on the NYSE American under the symbols "ACAQ," "ACAQ.U" and "ACAQ WS," respectively, until the consummation of the Business Combination.

17:33 EDT Palantir awarded $250M Army contract - Palantir was awarded a $250M firm-fixed-price contract to conduct research and development services in the area of artificial intelligence and machine learning. Work locations and funding will be determined with each order, with an estimated completion date of September 25, 2026. Army Contracting Command is the contracting activity.

17:19 EDT Hayward to replace Civitas Resources in S&P 600 at open on 9/29

17:15 EDT Weave partners with Affirm to expand payment options for patients - Weave (WEAV), "an all-in-one experience platform for small and medium-sized healthcare businesses," announced a new partnership with Affirm (AFRM), the payment network that empowers consumers and helps merchants drive growth. Now available to thousands of Weave's customers, this collaboration provides flexible payment options for eligible patients, making it easier for them to access and afford the care they need. By partnering with Affirm, Weave customers can offer their patients pay-over-time financing with as low as 0% APR. Affirm is directly integrated with Weave payments, so patients can apply to pay with Affirm in a matter of seconds, and spread out their payments over time, easing the burden of upfront costs and providing an additional payment option for dental, optometry, veterinary, or medical practices. This partnership will not only benefit patients but also allow healthcare practices to receive payments quicker than before.

17:09 EDT Dell Technologies names Steve Mollenkopf to board of directors - Dell Technologies (DELL) has appointed Steve Mollenkopf as its newest independent member of the Dell Technologies board of directors, effective Sept. 27, 2023. Additionally, Simon Patterson, managing director of Silver Lake, has resigned as a member of the board of directors, effective Sept. 26, 2023. With the appointment of Mollenkopf, the Dell Technologies board of directors now seats eight directors, six of which are independent members. Steve Mollenkopf served as the CEO of Qualcomm (QCOM) from 2014 to 2021.

17:03 EDT Golden Sun Education Group discloses Nasdaq listing deficiency notice - Golden Sun Education "announced that the company received written notification from the Nasdaq Stock Market LLC on September 22, 2023, notifying the company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on Nasdaq."

17:01 EDT mCloud Technologies to delist from Nasdaq - mCloud Technologies announced it would not meet the listing requirements of the Nasdaq Stock Market LLC. As such, Nasdaq has determined it will delist the Company's securities.

16:57 EDT Morphic CEO Dr. Praveen Tipirneni takes leave after 'emergent medical event' - Morphic Holdings announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence. Dr. Tipirneni is expected to return to his role as Chief Executive Officer after he recovers. In the interim, Morphic's executive team, led by Dr. Bruce Rogers, President and Dr. Marc Schegerin, COO and CFO, will continue with its leadership in day-to-day operational activities on a normal basis. "Praveen's health and continued recovery is the only focus for him and his family. We are sending them our thoughts and support and we look forward to him returning in good health," said Gustav Christensen, Morphic's Chairman of the Board of Directors. "In the meantime, our highly seasoned and experienced executives will work collaboratively, as always, to maintain business operations and ensure that the Company's strategic objectives remain on track during Praveen's leave." Morphic expects no interruptions or changes to its business operations and will provide an update on Dr. Tipirneni's health as soon as is practicable. The Company remains confident in its differentiated proprietary pipeline and MInT platform technology to treat the high unmet need of serious chronic diseases, including the development prospects for MORF-057 in IBD.

16:27 EDT MillerKnoll jumps 16% to $22.25 after Q1 results beat, FY24 guidance raised

16:17 EDT PPG names Tim Knavish as new CEO - PPG "announced that its Board of Directors has unanimously elected PPG president and chief executive officer, Tim Knavish as chair of the company's Board of Directors and CEO, effective Oct. 1, 2023. Knavish succeeds Michael McGarry, who served as chairman and CEO from 2016 to 2022 and is retiring as executive chairman, also effective Oct. 1, 2023. Knavish joined PPG in 1987 at PPG's global headquarters in Pittsburgh and he has held roles of increasing responsibility during his 36 years with the Company."

16:16 EDT Peloton appoints Nick Caldwell as Chief Product Officer - Peloton announced the appointment of Nick Caldwell as Chief Product Officer, or CPO, effective November 1. A Silicon Valley veteran with more than 20 years of global leadership experience, Caldwell joins the team with a proven track record of building and scaling products and services that excite customers, drive business growth, and deliver impact. Caldwell succeeds Peloton Co-Founder, Tom Cortese, and will report to CEO Barry McCarthy, leading global product development. As Co-Founder and Chief Product Officer, Cortese helped push Peloton into new areas of fitness and innovation. As of November 1 Cortese will move into an advisory role with the company, continuing to support its vision and growth.

16:15 EDT Industrial Logistics Property Trust names Tiffany Sy as new CFO - Industrial Logistics Properties "announced that Tiffany Sy has been appointed as Chief Financial Officer and Treasurer, effective October 1, 2023. Ms. Sy has served in finance and accounting leadership roles at The RMR Group (Nasdaq: RMR) since 2020."

16:13 EDT Cardiff Oncology announces results from trials in mPDAC and SCLC - Cardiff Oncology announced positive clinical data with onvansertib monotherapy and combination therapy in our ongoing trials in metastatic pancreatic ductal adenocarcinoma, or mPDAC, and small cell lung cancer, or SCLC, as well as plans for a mPDAC first-line investigator-initiated trial, or IIT, of the combination of onvansertib plus standard-of-care, or SoC. Data from the ongoing Phase 2 open-label trial of onvansertib combined with nanoliposomal irinotecan, leucovorin, and 5-FU in patients with second-line mPDAC demonstrated an objective response rate, or ORR, of 19% and median progression-free survival (mPFS) of 5.0 months as of the data cutoff of September 13. Historical control trials in similar patient populations have shown an ORR of 7.7% and mPFS of 3.1 months with SoC. The investigator-initiated biomarker discovery trial is exploring the impact of onvansertib 10-day monotherapy on tumors in mPDAC patients, and is currently enrolling at the Oregon Health & Science University Knight Cancer Institute. Two patients have been enrolled to date. One patient demonstrated an 86% decrease in Ki67, a well-established biomarker of tumor proliferation, and a 28% decrease in CA 19-9, a clinically-used biomarker to monitor treatment response. The next trial in mPDAC will be a new Phase 2 investigator-initiated trial at OHSU Knight Cancer Institute in mPDAC in the first-line setting. There are two cohorts in this trial. In cohort 1, patients will receive the combination of onvansertib with SoC. In cohort 2, patients will receive 10 days of onvansertib monotherapy followed by onvansertib + SoC to identify biomarkers that predict response to onvansertib.

16:10 EDT ShiftPixy says reverse stock split to become effective September 30 - ShiftPixy announced that at 11:59:59 p.m. on September 30, 2023, in Wyoming, pursuant to the vote of its shareholders on August 21, 2023, to effect a one-for-twenty-four (1:24) reverse split of the Company's issued and outstanding shares of Common Stock, as further detailed in the Company's definitive Schedule 14C Information Statement filed on September 1, 2023, Articles of Amendment of the Company's Amended and Restated Articles of Incorporation will become effective as filed with the Secretary of State of Wyoming. The new reversed shares will begin trading on Nasdaq on October 2, 2023.

16:06 EDT American Outdoor Brands secures patent settlement with The Allen Company - American Outdoor Brands announced that it has secured a settlement, including a permanent injunction entered by the United States District Court for the District of Colorado on September 25, 2023, with The Allen Company, related to Allen's infringement of AOB's patent rights. AOB's trademark and patent infringement action against Allen was initiated in February 2023 and was related to Allen's alleged repeated infringement of AOB's patent rights incorporated in the LEAD SLED shooting rests; Orange Peel shooting targets; and Ultimate Target Stand through Allen's sales of the Shottrax and Shot-Rock shooting rests; EZ Aim targets; and the Precision Target Stand, respectively. On September 25, 2023, the United States District Court for the District of Colorado entered a permanent injunction against Allen enjoining Allen from making, using, importing, selling, or offering for sale Shottrax and Shot-Rock shooting rests SKU Nos. 21922 and 21925; EZ Aim targets SKU Nos. 15253, 15229, 15224, 15222, 15228, 15225, 15252, 15226, and 15223; and the Precision Target Stand SKU No. 15296.

16:06 EDT Velo3D CFO McCombe resigns - Velo3D announced William McCombe has resigned as the company's Chief Financial Officer, effective September 29, 2023, to pursue other career opportunities. Bernard Chung, Velo3D's Vice President of Finance has been appointed Acting CFO, effective September 29, 2023. McCombe has agreed to stay on in a transition capacity through November 7, 2023 and will participate in the company's third quarter earnings conference call on November 7, 2023. "I want to thank Bill for his dedication and leadership over the last three years as he guided the company through the listing process and helped successfully grow Velo3D into one of the leading technology suppliers in the additive manufacturing industry," said Benny Buller, CEO of Velo3D. "I wish Bill the best of luck in his future endeavors. I am also pleased to welcome Bernie as our Acting Chief Financial Officer and look forward to continuing to build on our 3-year partnership. Given his more than 20 years of finance experience, we expect a seamless transition as he takes on his new responsibilities."

16:03 EDT Galecto to explore strategic alternatives, reduce workforce by 70% - Galecto announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives. As part of this evaluation process, Galecto will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, divestiture of its assets, technologies or capabilities, or other transaction. There can be no assurance that its exploration will result in Galecto pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all. In connection with the evaluation of strategic alternatives, Galecto plans to implement a restructuring plan that includes reducing its workforce by approximately 29 people, or approximately 70% of its existing headcount. Galecto has not set a timetable for completion of the evaluation process and does not intend to disclose further developments or guidance on the status of its programs unless and until it is determined that further disclosure is appropriate or necessary. As of June 30, Galecto's cash, cash equivalents and investments balance was $52.1M.

15:58 EDT NYIAX enters into settlement pact, release with Boustead Securities - According to a regulatory filing, on September 20, 2023, NYIAX entered into a Settlement Agreement and Release with Boustead Securities, LLC to settle any and all potential claims and counterclaims that may arise from the consummation of certain financing transactions pursuant to that certain engagement letter, dated March 23, 2021, by and between the company and Boustead. In March 2023, the company delivered notice of termination of the Engagement Letter to Boustead and subsequently engaged another underwriter to complete its initial public offering. Boustead has claimed that under the Engagement Letter, the company owes or will owe Boustead approximately $1M for commissions on funds privately raised by the company during its engagement with Boustead and approximately $1,230,000 if the company completes an IPO with another underwriter. The company disputes the amounts owed that have been claimed by Boustead. Pursuant to the terms of the Agreement, and in order to settle the dispute with Boustead amicably and efficiently, the company and Boustead have agreed to a contingent mutual release and waiver of claims in exchange for a cash payment of $515,000 by the Company to Boustead as a deduction from the offering proceeds upon consummation of the company's IPO. The Agreement also provides Boustead for certain indemnification under Section 4 of the Engagement Letter. Unless otherwise amended, the Agreement shall be deemed null and void in the event the company's IPO is not consummated by December 31, 2023. If the settlement is finalized with the consummation of the company's initial public offering, the company does not anticipate any additional charges related to this threatened litigation.

15:05 EDT FCC Chair proposes to restore 'net neutrality' rules - Chairwoman Rosenworcel shared with her colleagues a proposal that would begin the process of re-establishing the FCC's oversight over broadband and restoring uniform, nationwide net neutrality rules, the FCC announced. Companies that have made public statements regarding "net neutrality" or could be impacted by the rules include Netflix (NFLX), AT&T (T), Verizon (VZ), Comcast (CMCSA), Charter (CHTR), Amazon (AMZN), Apple (AAPL), Google (GOOGL), Meta (META), Disney (DIS), Warner Bros. Discovery (WBD), Paramount (PARA) and Sony (SONY). Reference Link

14:40 EDT AutoNation confirms submitted non-binding preliminary proposal to buy Pendragon - In a regulatory filing, AutoNation (AN) stated: "On September 26, 2023, Pendragon PLC (PDNGF) issued an announcement stating that AutoNation submitted a non-binding, preliminary proposal to acquire the entire issued and to be issued share capital of Pendragon. Following its receipt of the Proposal, the board of directors of Pendragon publicly announced that they intend to consider the Proposal and will consult with their shareholders and provide an update in due course... There can be no certainty as to whether the Company will make a binding offer for Pendragon. The Company makes no representation as to the accuracy or completeness of the Pendragon Announcement, which was issued without the consent of the Company. The Company confirms that it has submitted to Pendragon a non-binding preliminary proposal to acquire Pendragon's entire issued and to be issued share capital for 32 pence per share and that the acquisition would not require approval by the Company's stockholders or include the issuance of any equity securities of the Company. The Company will make a further announcement if and when appropriate."

14:32 EDT Canada launching review of proposed acquisition of Viterra by Bunge - Canada's Minister of Transport, the Honourable Pablo Rodriguez, issued the following statement: "A strong transportation supply chain means more affordable, more available products for Canadians. In order to ensure that we have fair competition at Canada's ports, the Government of Canada is launching a review of the proposed acquisition of grain handler Viterra Limited by Bunge Limited, a global agricultural company. Both companies hold ownership interests in port terminals throughout our country. Healthy competition in the transportation sector is necessary to ensure fair pricing and access for users, especially for Canadian farmers. Given this transaction is of significant national interest in Canada's transportation sector and the broader supply chain, it will be reviewed under the mergers and acquisitions provisions of the Canada Transportation Act. Goods must continue to move smoothly, and our supply chain must continue to grow stronger. This is why the Government will launch a public interest assessment that will include consultations with Canada's ports and marine industry, stakeholders, other government departments, other orders of government, and Canadians. Transport Canada has up to 250 days, or until June 2, 2024, to complete the public interest assessment." Reference Link

13:37 EDT Wells Fargo, Centerbridge enter into strategic pact focused on direct lending - Centerbridge Partners and Wells Fargo & Company announced they are entering into a strategic relationship focused on direct lending to non-sponsor North American middle market companies. To meet the alternative credit needs of this segment, Centerbridge intends to launch Overland Advisors to manage a newly formed business development company that will be primarily focused on making senior secured loans. Overland represents a transformative new business model for direct lending to middle-market companies, diversifying the market of clients served by private credit and direct lending. The Centerbridge and Wells Fargo strategic relationship includes differentiated origination sourcing from Wells Fargo's extensive middle market customer base, and an equity investment from Wells Fargo. In addition to expanding financing access to the non-sponsor segment, Overland will pursue other transactions, including traditional sponsor-backed direct lending opportunities. Overland Advisors is targeting a minimum of $5B in investible capital, including $2.5B in equity commitments for this strategy. Anchor investors, including wholly owned subsidiaries of the Abu Dhabi Investment Authority and British Columbia Investment Management Corporation, have committed to provide nearly $2B in initial equity commitments. "Overland represents a new paradigm in direct lending, bringing a relationship approach to direct lending and offering a much-needed capital solution in the large but underpenetrated non-sponsor U.S. middle market," said Jeff Aronson, Co-Founder and Managing Principal of Centerbridge Partners. "We believe Overland draws on the unique and complementary capabilities of both Centerbridge's leading private credit underwriting capabilities and Wells Fargo's nationwide sourcing and origination network to offer an attractive new proposition for borrowers in the private lending and direct credit space at a particularly compelling time."

13:09 EDT Pendragon announces receipt of proposal from AutoNation - The board of directors of Pendragon (PDNGF) confirms that it has received an unsolicited proposal from AutoNation (AN) to acquire the entire issued and to be issued share capital of Pendragon for 32 pence per share, in cash, the company announced in a notice to the London Stock Exchange. "The AutoNation Proposal remains subject to a number of pre-conditions, including the completion of due diligence. The Board will consider the AutoNation Proposal and will consult with its shareholders and provide an update in due course. There can be no certainty that any firm offer will be made, nor to the terms of any such offer. Shareholders are advised to take no action at this time. As required by Rule 2.6(a) of the Code, AutoNation is required, by not later than 5.00 p.m. on 24 October 2023, either to announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or to announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline may be extended with the consent of the Takeover Panel in accordance with Rule 2.6(c) of the Code. The person responsible for arranging for the release of this announcement on behalf of Pendragon is Richard Maloney, Group General Counsel and Group Company Secretary. This announcement is made without the consent of AutoNation," the notice stated.

12:50 EDT Nutanix down 1% as investor day continues - Shares of Nutanix are down 51c, or 1%, to $34.87 as the company continues to conduct its investor day meeting. Reference Link

12:20 EDT FirstEnergy board raises quarterly dividend 5% to 41c per share - The Board of Directors of FirstEnergy declared a quarterly dividend of 41c per share of outstanding common stock payable December 1, 2023, to shareholders of record at the close of business on November 7, 2023. This represents a 5% increase compared to quarterly payments of 39c per share paid by the company since March 2020.

12:10 EDT FDA website posts approval of Ocuphire Pharma's Ryzumvi - Reference Link

12:05 EDT FTC, 17 states sue Amazon for maintaining 'monopoly power' strategies - The Federal Trade Commission and 17 state attorneys general sued Amazon.com, alleging the company "is a monopolist that uses a set of interlocking anticompetitive and unfair strategies to illegally maintain its monopoly power." The FTC and its state partners say Amazon's actions "allow it to stop rivals and sellers from lowering prices, degrade quality for shoppers, overcharge sellers, stifle innovation, and prevent rivals from fairly competing against Amazon." The complaint alleges that Amazon "violates the law not because it is big, but because it engages in a course of exclusionary conduct that prevents current competitors from growing and new competitors from emerging." By stifling competition on price, product selection, quality, and by preventing its current or future rivals from attracting a critical mass of shoppers and sellers, Amazon ensures that no current or future rival can threaten its dominance, the FTC said in a statement. The FTC, along with its state partners, are seeking a permanent injunction in federal court "that would prohibit Amazon from engaging in its unlawful conduct and pry loose Amazon's monopolistic control to restore competition. Connecticut, Delaware, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New Hampshire, New Mexico, Nevada, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, and Wisconsin joined the Commission's lawsuit. Reference Link

12:01 EDT FTC files antitrust suit against Amazon for marketplace monopoly

12:00 EDT Allurion Technologies falls -9.1% - Allurion Technologies is down -9.1%, or -47c to $4.68.

12:00 EDT Heritage Insurance rises 15.8% - Heritage Insurance is up 15.8%, or 83c to $6.09.

12:00 EDT Fisker rises 20.5% - Fisker is up 20.5%, or $1.09 to $6.40.

10:55 EDT Willis Towers Watson increases share repurchase program by $1B - WTW announced that its board of directors approved an increase to the existing share repurchase authority in the amount of $1B. The $1B increase is in addition to the approximately $545M remaining on the current open-ended repurchase authority. "The company is authorized to repurchase shares, by way of redemption or otherwise, and will consider whether to do so from time to time, based on many factors, including market and economic conditions, applicable legal requirements and other business considerations," WTW stated.

10:41 EDT Commercial Vehicle Group opens manufacturing facility in Morocco - CVG announced the opening of its new manufacturing facility in Tangier, Morocco. This expansion represents CVG's commitment to its global electrification business growth and its first significant presence in Africa. The plant will initially offer approximately 30,000 square feet of manufacturing space and will produce electrical wire harnesses for the automotive industry. By 2024, CVG has plans to significantly increase the square footage with the capacity to produce hundreds of thousands of wire harnesses per year for additional industries including agriculture, construction, and more. This strategic location will serve as a pivotal hub in CVG's global network while supporting the local economy in Tangier. The facility will initially create 250 jobs, with greater job expansion planned in the future. CVG extends its gratitude to the Moroccan government and local authorities for their unwavering support throughout this venture.

10:08 EDT JPMorgan reaches $75M settlement with U.S. Virgin Islands over Epstein - JPMorgan announced an agreement to pay the U.S. Virgin Islands $75M to settle a lawsuit alleging the bank aided Jeffrey Epstein's sex trafficking. "JPMorgan Chase believes this settlement is in the best interest of all parties. While the settlement does not involve admissions of liability, the firm deeply regrets any association with this man, and would never have continued doing business with him if it believed he was using the bank in any way to commit his heinous crimes," the bank said in a statement.

10:04 EDT Fast Acquisition Corp II trading resumes

10:03 EDT Correction: Repligen to acquire Metenova - This note corrects a prior alert that incorrectly stated in its headline that Regeneron had agreed to acquire Metenova AB.

10:00 EDT Graf Acquisition IV falls -8.3% - Graf Acquisition IV is down -8.3%, or -79c to $8.70.

10:00 EDT United Natural Foods falls -14.8% - United Natural Foods is down -14.8%, or -$2.80 to $16.12.

10:00 EDT Fisker rises 11.0% - Fisker is up 11.0%, or 58c to $5.89.

09:59 EDT Fast Acquisition Corp II trading halted, volatility trading pause

09:47 EDT Daily S&P Biotech Bear 3x Shares falls -6.7% - Daily S&P Biotech Bear 3x Shares is down -6.7%, or -$1.45 to $20.23.

09:47 EDT United Natural Foods falls -20.0% - United Natural Foods is down -20.0%, or -$3.79 to $15.13.

09:47 EDT Methode Electronics rises 5.5% - Methode Electronics is up 5.5%, or $1.20 to $23.20.

09:34 EDT Lilium starts assembly of Lilium Jet's electric propulsion system - Lilium is starting assembly of the Lilium Jet's electric propulsion system at its dedicated propulsion facility located next to its headquarters in Wessling, Germany. The announcement marks another exciting milestone on the targeted path towards industrialization and commercial entry into service of the Lilium Jet and reconfirms Lilium's roadmap towards achieving first manned flight of the aircraft in late 2024.

09:25 EDT Kuke Music receives continued listing standard notice from NYSE - Kuke Music announced that on June 29, 2023, it received a notice from the New York Stock Exchange that it is no longer in compliance with the NYSE's continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million and its shareholders' equity was less than $50 million. As set forth in the Notice, as of June 27, 2023, the 30 trading-day average global market capitalization of the Company was approximately $20.7 million and the Company's last reported shareholders' equity as of December 31, 2022 was $8.8 million. In accordance with the NYSE's listing requirements, the Company has notified the NYSE that it will submit a plan within 45 days of the Notice advising the NYSE of the definitive action it has taken, or is taking, to bring it into conformity with Section 802.01B within 18 months of receipt of the Notice.

09:22 EDT Ideal Power adds global power conversion supplier to B-TRAN program - Ideal Power announced a European-based global power conversion and energy storage supplier with over $500 million in annual sales entered into an agreement with Ideal Power to test and evaluate B-TRAN power semiconductors for its static switches in data center UPS systems, solar inverters, and energy storage products. Their focus is on improving energy efficiency in these products to reduce operating costs for their customers.

09:20 EDT Matterport announces next generation of AI-powered real estate insights - Matterport introduces the next generation of intelligent digital twins with powerful new capabilities fueled by the company's rapid advancements in AI and data science. Now in beta, customers can access automated measurements, layouts, editing, and reporting capabilities generated from their digital twins. "I'm excited to see the progression of our digital twins helping customers put AI and automation to practical use for their properties," said RJ PIttman, Chairman and CEO of Matterport. "Instant access to room dimensions, total square footage by room, floor, and the entire space, builds upon one of our most popular features - Measurement Mode. With our new intelligent digital twins, our customers get hundreds of useful measurements, room names, print-ready layouts and more - automatically. With these new 'power tools' we're driving customer productivity through the roof!"

09:18 EDT Blink Charging advances almost 2% after announcing deal with Parkopedia - Shares of Blink Charging, "a global manufacturer, owner, operator and provider of electric vehicle charging equipment and services," are up almost 2% to approximately $3.03 per share in the pre-market on Tuesday after announcing a deal with Parkopedia, "a global connected car and parking services provider," to integrate over 4,000 Blink EV charging locations onto the Parkopedia platform in North America. "Our collaboration with Parkopedia creates a streamlined experience for EV drivers to conveniently locate Blink EV charging stations across North America," said Jim Nemec, Chief Revenue Officer for Blink Charging. "The combination of Parkopedia's excellence in serving drivers through convenience in parking accessibility and Blink's extensive range of public EV chargers gives EV drivers confidence in finding a reliable charging experience wherever they are. This initiative builds upon our strategy of making it easy for EV drivers to locate Blink chargers through a variety of platforms."

09:17 EDT EnWave signs commercial license agreement with Michael Foods - EnWave Corporation has signed a commercial royalty-bearing license with Michael Foods. Michael Foods has also purchased a 10kW Radiant Energy Vacuum machine from EnWave after conducting product development research and development over the past several months. The License grants Michael Foods the right to produce certain products using REV technology in the United States of America and provides for an ongoing royalty stream tied to the commercial sales of any REV-dried products produced and sold by Michael Foods during the term. The License is the fifty-third active royalty-bearing agreement issued by EnWave.

09:15 EDT VivoPower's Tembo signs definitiev joint venture agreement with Francisco Motor - Tembo, a subsidiary of the NASDAQ listed B Corp, VivoPower International, announces that it has signed a definitive joint venture agreement with Francisco Motor, the pioneering manufacturers of the iconic jeepneys in the Philippines, which are primarily used for public transportation. Pursuant to the Agreement, Tembo will develop and supply electric utility vehicle electrification kits for a new generation of electric jeepneys. Francisco Motors and Tembo have already secured their first orders and have commenced work to deliver on these jeepneys. Kevin Chin, VivoPower's Executive Chairman and Chief Executive Officer, said: "We are honoured to have signed this exclusive definitive agreement with Francisco Motor Corporation to electrify the jeepneys, a much-loved cultural icon in the Philippines. Francisco Motors are the original pioneers of the jeepney, launching in 1947 post the ending of World War II. We stand in solidarity with Elmer Francisco, Chairman of Francisco Motors, in our shared mission to electrify and rejuvenate the jeepney in a manner that preserves the original design and look, as well as importantly improves the livelihood of the people employed by the jeepney industry.

09:14 EDT Microchip releases PIC18-Q20 family of microcontrollers - With the step-function increase in data collected and transmitted from cloud-connected edge nodes, Improved Inter Integrated Circuit is rapidly becoming a more sustainable solution for interfacing sensors with a high data rate and will help expand capabilities in next-generation devices. Leading the way in I3C integration, Microchip Technology has released its PIC18-Q20 family of microcontrollers, the industry's first low pin count MCUs with up to two I3C peripherals and Multi-Voltage I/O. Available in 14- and 20- pin packages as small as 3 x 3 mm, the PIC18-Q20 MCUs are a compact solution for real-time control, touch sensing and connectivity applications. The MCUs offer configurable peripherals, advanced communication interfaces and easy connection across multiple voltage domains without external components.

09:12 EDT Castor announces sale of M/V Magic Argo, termination of sale of M/V Magic Moon - Castor Maritime announces that on September 22, 2023, the Company entered into an agreement with an unaffiliated third party for the sale of the M/V Magic Argo, a 2009-built Kamsarmax bulk carrier, for a price of $15.75 million. The vessel is expected to be delivered to her new owners during the fourth quarter of 2023.The Company expects to record during the fourth quarter of 2023 a net gain of approximately $3.0 million, excluding any transaction-related costs. The Company also announces that the previously announced sale of the M/V Magic Moon was terminated following the buyer's failure to take delivery of the vessel. Accordingly, the Company will retain the vessel and not receive its purchase price of $13.95 million, that would have incorporated a net gain before transaction costs of $5.3 million. The Company is seeking appropriate compensation pursuant to the terms of the Memorandum of Agreement for this sale.

09:10 EDT Sadot reports topline revenue over $67M in August - Sadot Group has achieved top line revenue of over $67.8 million for the month of August 2023. This announcement marks the tenth consecutive month in which top line revenue has exceeded $45 million and comes on the heels of the Company's first-ever profitable quarter. "With the Company's strategic pivot into the global agri-foods supply chain sector ten months ago, we have been laser-focused on executing against our growth strategies across all facets of our business, including operational verticals and geographical areas of operations," said Sadot Group CEO, Michael Roper. "It is important to note that August's top line results includes our first trades in the Americas from our newly-formed subsidiary, Sadot Latam LLC."

09:08 EDT MobileX announces multi-year exclusivity agreement with Walmart - MobileX announced a multi-year exclusivity agreement with Walmart. MobileX first introduced customized prepaid mobile plans in February 2023 which will now be available on walmart.mymobilex.com and in select stores nationwide.

09:07 EDT Vera Bradley announces 2024 annual outlet sales date - Vera Bradley will host its 38th Annual Outlet Sale event at the Allen County War Memorial Coliseum in Fort Wayne, Ind. from May 1 - May 5, 2024. The first three days of the Vera Bradley Annual Outlet Sale will offer multiple ticketed sessions for shoppers to take advantage of the best selection of Vera Bradley handbags, travel items, accessories, stationery and luggage in a variety of current and retired patterns along with bracelets and other items from VRA-owned lifestyle brand Pura Vida. The last two days of the Sale will be open to the public with no ticket required to enter.

09:06 EDT Progress Software announces partnership with SIG - Progress announced a partnership with Software Improvement Group, SIG, an independent technology and advisory firm for software quality, security and improvement, to help ensure the long-term maintainability and modernization of business-critical applications built on the Progress OpenEdge platform. This collaboration provides OpenEdge customers with automated guidance through Sigrid, SIG's software assurance platform, on areas to focus on when addressing technical debt and modernizing applications. "Our partnership with SIG is important as it provides a unique opportunity to extend the value that OpenEdge provides by offering greater insight into the quality of the application code supporting mission-critical applications that our customers depend on," said John Ainsworth, Executive Vice President, General Manager, Application and Data Platform, Progress.

09:05 EDT Cano Health sells primary care centers in Texas and Nevada for $66.7M - Cano Health sold substantially all of the assets associated with the operation of Cano Health's senior-focused primary care centers in Texas and Nevada to CenterWell Senior Primary Care. The total value of the transaction to Cano Health is approximately $66.7M, consisting of approximately $35.4M in cash paid at closing, plus the release of certain liabilities owed by Cano Health. As of August 1, the primary care centers in Texas and Nevada cared for approximately 15,200 members. Cano Health expects that the net cash proceeds from this transaction will enable it to remain in compliance with the covenants under its debt instruments at the end of Q3. Following the transaction, Cano Health has available liquidity consisting of approximately $109M of unrestricted cash. Cano Health intends to use approximately $80M of such cash to repay a portion of its $120M revolving credit facility by the end of Q3 2023. This will enable Cano Health to remain below the $42M threshold drawn amount and thus avoid being required to comply with the financial maintenance covenant under its Credit Suisse credit agreement for the testing period ending September 30, 2023. The remaining balance will be available for general corporate purposes. The $80M of planned repayments under the revolving credit facility will remain available for future borrowings.

09:05 EDT Jack Henry, Marstone team on seamless access to digital wealth & banking - Marstone announced its collaboration with Jack Henry. The partnership allows bank customers who use Jack Henry's Banno digital banking platform to also access Marstone's digital wealth platform via a single sign-on SSO . Marstone leveraged the Banno Digital Toolkit the same set of APIs the Banno Digital Platform is built on, to embed its technology into the digital experiences offered by community and regional financial institutions. Access to Jack Henry's API, design and authenticated frameworks has enabled Marstone to directly integrate into the digital banking platform, providing a seamless banking experience. This integration has contributed to Jack Henry's growing ecosystem of more than 850 fintechs, providing nearly 8,000 financial institutions with relevant financial products and services for their account holders.

09:04 EDT GeoVax secures multi-product license for ProBioGen's AGE1.CR.pIX line - GeoVax Labs and ProBioGen announce the signing of a landmark commercial license agreement for ProBioGen's groundbreaking AGE1.CR.pIX suspension cell line. The agreement will empower GeoVax to enhance the manufacturing capabilities of its entire Modified Vaccinia Ankara based vaccine portfolio. ProBioGen's AGE1.CR.pIX suspension cell line is an innovative and proven platform that enables high-yield and scalable production, ensuring efficient industrial manufacturing processes. This translates to cost-effectiveness and increased productivity for vaccine developers. The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types, enhancing its suitability for various vaccines in development and as a replacement for traditional production systems. Additionally, AGE1.CR.pIX's robust growth and genetic stability ensure consistent and reliable production, leading to the delivery of safe and effective vaccines. MVA grows particularly well on this cell line, making it even more advantageous for vaccine development. By leveraging this modern production technology, GeoVax aims to accelerate the manufacturing of its entire vaccine pipeline. This multi-product license represents a strong commitment to improving global access to life-saving vaccines. Financial terms of the commercial license to use the AGE1.CR.pIX, including potential clinical milestones and future royalties were not disclosed.

09:03 EDT Synaptogenix's Bryostatin-1 in Alzheimer's featured in peer-reviewed publication - Synaptogenix announced a peer-reviewed publication of statistically significant integration of secondary and exploratory endpoint data from its previously completed Phase 2 trial of Bryostatin-1 for Alzheimer's disease. As stated in the paper, conclusions from analyses of the trial's Severe Cohort indicate that Bryostatin-treated MMSE 10-14 patients showed no significant cognitive decline throughout the 10-month trial, compared with placebo patients' decline of -12.8 SIB points. The paper goes on to discuss persistence in the data, stating, "The prolonged absence of any significant cognitive decline in Bryostatin-treated patients vs. placebo patients - even 16 weeks after the final dose of Bryostatin - suggests a long-lasting positive change in the treated patients' brains." The data demonstrates that Bryostatin-1-treated patients in the Severe Cohort showed statistically significant improvement of cognitive performance over placebo patients for weeks #13 through #42, with the last dose administered at Week #26.

09:02 EDT Galaxy Gaming delivers operating system across Carnival fleet - Galaxy Gaming announced that they will deliver Galaxy Operating System as the table games system for 50+ ships across the globe with Carnival Corporation & plc. Already live on over 20 ships, GOS will power the jackpot progressive system for Carnival Corporation ships, including Carnival Cruise Line, Holland America Line, and Princess Cruises.

08:59 EDT U-Blox announces LEXI-R10 module - u-blox has announced its LEXI-R10, an ultra-small LTE Cat 1bis IoT module in a 16 x 16mm form factor. The module adapts perfectly to size-demanding designs, making it ideal for use cases such as asset tracking and aftermarket telematics. Three times smaller than the u-blox LENA-R8, LEXI-R10 is the answer to the market need for an ultra-small LTE Cat 1bis module and is the perfect candidate for applications requiring Cat 1bis connectivity without 2G fallback or positioning features. It has been designed as a single-mode LTE-only module. Yet, LENA-R8 is still a reliable option for applications that need 2G fallback and positioning with the embedded u-blox M10 GNSS platform.

08:58 EDT Ayro to host test drive event at Texas headquarters - AYRO announces that the Company will host an exclusive opportunity for individuals to drive the Company's utility low-speed electric vehicle, the AYRO Vanish at the Company's headquarters in Round Rock, Texas on October 19, 2023. The Vanish offers adaptable payloads to meet a myriad of needs for fleet, commercial and personal use. The Vanish recently completed California Air Resources Board testing certification, and has also completed homologation for both the United States and Canada by demonstrating compliance with Federal Motor Vehicle Safety Standards, Canada Motor Vehicle Safety Standards and SAE J2358. The Vanish is currently in low-rate initial production with availability of the vehicle for dealers and partners expected to follow shortly.

08:55 EDT Ondas' Airobotics completes Optimus Drone Infrastructure PoC program - Ondas Holdings' Airobotics has successfully completed a proof-of-conceptof the Optimus Drone Infrastructure in the Haifa port area. The PoC was conducted with the Israel Port Company, which is responsible for planning, development, construction, maintenance, and enhancement of Israel's commercial seaports in Haifa, Ashdod, and Eilat. With the successful completion of the PoC, Airobotics and IPC will be working on advancing the deployment of Optimus in the Haifa port area.

08:54 EDT Vicinity Motor receives order for four Vicinity Classic buses - Vicinity Motor announced the receipt of a new purchase order from the Village of New Square, New York for four Vicinity Classic buses. Per the terms of the supply agreement, the Village of New Square has ordered four of the Company's 32-foot Clean-Diesel Vicinity Classic buses for delivery in the fourth quarter of 2023. The Vicinity buses will service New Square, a village north of New York City, providing enhanced mobility solutions through the low-floor design - which includes an automatic personal mobility aid access ramp for wheelchairs.

08:52 EDT One Stop Systems secures award for submarine sonar data processing system - One Stop Systems has received an order to design and develop prototypes for a sonar data processing system to be used in a foreign navy submarine application. "We are pleased to be recognized in this award for our unmatched ability to deliver a ruggedized edge processing solution with datacenter class processing within strict SWAP, thermal and noise requirements," stated OSS CEO Mike Knowles. "The win also reflects our progress in leveraging OSS Europe to expand our global reach and customer base." OSS will design and build a liquid-cooled high-performance compute solution that will be deployed on submarines. OSS expects to deliver the first prototypes by the end of the year, followed by potential production orders in 2024.

08:49 EDT Protagenic Therapeutics initiates Phase I/IIa trial for PT00114 - Protagenic Therapeutics has announced the commencement of its Phase I/IIa clinical trial for PT00114, its leading drug candidate. Key Highlights: Clinical Trial Focus: The trial aims to evaluate the therapeutic potential of PT00114, a synthetic version of the naturally occurring brain peptide TCAP, in treating an array of neuro-psychiatric conditions, including depression, anxiety, and PTSD. PT00114 is a novel first in class peptide which has shown profound activity with a novel mechanism in disease models of those three conditions, as well as in treating models of addiction withdrawal. Study Design: Phase I will recruit 56 subjects, randomized to undergo subcutaneous injections of either PT00114 or a placebo. The Phase I/IIa study will assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD, and Generalized Anxiety Disorder. Progress Indicators: Besides monitoring disease status, the trial will gauge disease response by measuring biomarkers, such as circulating cortisol levels before and after treatment. Partnership: Axiom Real-Time Metrics, a CRO/Data Analytics firm with over 1,000 clinical trials to its credit, is managing the clinical program.

08:48 EDT Ensysce Biosciences completes site initiation visit for PF614-201 study - Ensysce Biosciences announced the Site Initiation Visit was completed for the PF614-201 study, 'A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614 on Analgesic Response in the Cold Pressor Test in Healthy Male Subjects' to evaluate time of onset for PF614. The study is being conducted by Dr. George Atiee at Dr. Vince Clinical Research in Overland, KS.

08:47 EDT Sharps sign asset purchase agreement to acquire InjectEZ manufacturing facility - Sharps Technology and Nephron Pharmaceuticals announce the signing of an Asset Purchase Agreement to acquire Nephron's InjectEZ specialty syringe manufacturing facility. This includes a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals for next-generation copolymer prefillable syringe systems. Product delivery is scheduled for the first quarter of 2024 with revenue totaling approximately $30 Million for the first twelve months of production and subsequent revenue of over $45 Million per year beginning in 2025, and continuing through 2033. s a result of the proposed acquisition of InjectEZ, Nephron has agreed to a 10-year Purchase Agreement for Sharps' next-generation copolymer prefillable 10 mL and 50 mL syringes with minimum orders for over $400 Million over the period. Product delivery is scheduled for the first quarter of 2024 with revenue totaling approximately $30 Million for the first twelve months of production, with subsequent revenue of over $45 Million per year beginning in 2025, and continuing through 2033. To finance the acquisition, Sharps retained Lampert Capital Advisors, a provider of complex financing solutions to publicly traded, privately held, and entrepreneurially backed companies. Lampert is engaged in a financing process that has resulted, to date, in a signed term sheet with a leading middle-market lender for up to $75 Million in debt financing to be used for the acquisition of InjectEZ, production line enhancements, working capital, transaction fees and expenses, and general corporate purposes.

08:44 EDT Alkaline Water now In full compliance with NASDAQ's periodic filing requirement - The Alkaline Water Company announced it has received formal notification from The Nasdaq Stock Market that it is now in compliance with the Nasdaq's periodic filing requirements. Previous deficiency notifications received from The Nasdaq Stock Market on July 18 and August 23, 2023, and subsequently disclosed by the Company, have been fully remedied by the Company. "I am pleased the Company has remedied its filing deficiencies. Going forward, it is imperative that the Company timely file all of its periodic financial reports, and I have taken the necessary steps to ensure timely reporting going forward," stated Frank Chessman, President and CEO of The Alkaline Water Company.

08:43 EDT 3D Systems receives $10.8M contract award from U.S. Air Force - 3D Systems announced it has been awarded a $10.8M U.S. Air Force contract for a Large-format Metal 3D Printer Advanced Technology Demonstrator. The contract supports the development of large-scale hypersonic-relevant additive manufacturing print capabilities. Work will be performed in Rock Hill, South Carolina, and in San Diego, California with an expected completion date of September 29, 2025. This contract builds upon 3D Systems' history of working in support of the U.S. Department of Defense/Government since 2019 for the advancement of additive manufacturing. "We're pleased to have been awarded this contract and are confident that it will extend the state of the art in metal additive manufacturing within the United States," said Dr. Jeffrey Graves, president & CEO, 3D Systems. "We look forward to working with the United States Air Force to meet the objectives of this project."

08:42 EDT Arcturus and CF Foundation extend pact to advance ARCT-032 - Arcturus Therapeutics Holdings announced that Arcturus and the Cystic Fibrosis Foundation CF Foundation have extended their ongoing agreement. The CF Foundation agreed to increase its financial commitment to ~$25M to advance ARCT-032, a novel messenger RNA mRNA therapeutic candidate formulated with Arcturus' LUNAR delivery technology. This agreement extends a prior research program, initiated in 2017, which has resulted in the advancement of ARCT-032 into ongoing clinical studies. "We are thrilled to extend our productive relationship with the Cystic Fibrosis Foundation, and we are grateful for their meaningful financial support," said Pad Chivukula, Ph.D., Chief Scientific Officer of Arcturus. "ARCT-032 has the potential to express fully functional CFTR protein in the lung, thereby addressing the root cause of cystic fibrosis. The resources and valuable expertise provided by the CF Foundation will support the continued clinical development of ARCT-032, including the completion of a Phase 1b study that we plan to initiate imminently in adults living with cystic fibrosis."

08:40 EDT Sportsman's Warehouse appoints Stone as CEO, McBee as next independent chair - Sportsman's Warehouse announced that its Board of Directors has appointed Paul Stone as the Chief Executive Officer and President of the Company and as a member of the Board, effective November 1, 2023. Stone's appointment follows an extensive search and selection process that considered both internal and external candidates. This process was led by the Board and conducted with the assistance of a leading independent executive search firm. Stone will succeed Joseph Schneider, who has served as Interim Chief Executive Officer and President since April 2023. Schneider will continue to serve as Independent Chair of the Board until the end of 2023, when he will retire from the Board and director Rich McBee will succeed him as Independent Chair. Stone is a seasoned executive with direct experience in the outdoor specialty retail space, having served as the Chief Retail Officer of Cabela's. Richard McBee has served as a member of the Sportsman's Warehouse Board since November 2018.

08:38 EDT RTX to expand GTF MRO capacity in Singapore - Pratt & Whitney, an RTX business, announced plans to increase the capacity of its Singapore engine center, Eagle Services Asia. The 48,000 square-foot expansion will accommodate a two-thirds increase from current facility capacity.

08:35 EDT KULR Technology, Forge Nano form strategic partnership - KULR Technology Group announced that it has entered into a Memorandum of Understanding, MoU, with Forge Nano, a global leader in precision nanocoating technology. The strategic partnership, initially estimated at a $3.5 million to $5 million revenue opportunity, will combine KULR ONE Design Solutions offerings that include cell characterization and advanced automated battery cell screening capabilities with Forge Nano's proprietary Atomic Layer Deposition coating process. This strategic partnership will start with the assessment of Forge Nano's premium battery cells for space and US Department of Defense applications employing KULR's automated cell screening to measure voltage, temperature, and impedance of individual battery cells, analyzing the data to identify potential issues and optimizing battery cell performance compliant within the strict NASA flight specification EP-WI-037 crucial for ensuring safety and reliability.

08:35 EDT Galmed granted new patent for aramchol in Japan - Galmed announced the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis. A similar patent was already granted in Mexico. The approval of the patent in the US and the rest of the world is pending. With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until November 2037.

08:34 EDT Panbela announces new patent in China for the production of SBP-101 - Panbela Therapeutics announced an Issue Notification for the Chinese patent 201980010826.7 titled "METHODS FOR PRODUCING -3,8,13,18- TETRAAZAICOSANE-6,15-DIOL". This patent, developed in collaboration with Syngene International Ltd., an integrated research, development, and manufacturing services company, claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101 , a lead investigational product. The patent is valid until 2039. Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela Therapeutics, commented, "This expansion of coverage into China and Asia as a whole, is significant for our patent portfolio and aligns with our global clinical programs. With a shorter synthesis of SBP-101, there are several advantages including a more scalable, efficient, and cost-effective manufacturing process. These benefits are essential for future efforts, as they can potentially reduce production costs and improve the overall competitiveness of SBP-101 in the market. Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Ltd., said, "We are delighted with the continued success of our longstanding collaboration with Panbela. Our partnership with them dates back to 2013 and since then we have collaborated on multiple projects. In this case, streamlining the production process of an investigational product is a core expertise in our Development Services division. A simpler production process means that commercialization will be easier, and the drug will reach patients more quickly. The protection of SBP-101 production through patents in multiple markets and now in China are significant milestones." Dr. Simpson added, "This achievement underscores the Company's commitment to protecting its intellectual property, advancing it's products on a global scale, which can potentially lead to a broader market access and increased opportunities for SBP-101's success."

08:33 EDT Sirius XM confirms receipt of proposal from Liberty Media - Sirius XM (SIRI) acknowledged that the special committee of independent directors of the board of SiriusXM received a non-binding proposal from Liberty Media (LSXMA) regarding a potential transaction involving the company. The potential transaction would consist of the separation of the assets and liabilities attributed to the Liberty SiriusXM tracking stock group from Liberty Media through the split-off of a newly formed company and the subsequent combination of Newco and SiriusXM, as a result of which the holders of Liberty SiriusXM tracking stock and SiriusXM common stock would all hold one class of common stock of the combined company. The Special Committee, together with its advisors, Solomon Partners Securities, LLC and Debevoise & Plimpton LLP, is evaluating the Proposal.

08:33 EDT iRhythm launches next generation Zio monitor, enhanced Zio service - iRhythm Technologies announced the U.S. launch of its next-generation Zio monitor and enhanced Zio long-term continuous monitoring service. "We've made our best product even better - early clinical and patient experience shows that Zio monitor has even better wear times, comfort and patient experience," said Mintu Turakhia, MD, MAS, Chief Medical Officer, Chief Scientific Officer and Executive Vice President, Product Innovation at iRhythm. "When you combine our new Zio monitor with our advanced AI, efficient workflow, patient and clinician apps, and easy-to-read and actionable clinical reports, we continue to lead the way in the field."

08:32 EDT Lightspeed reappoints Brouillette to board of directors - Lightspeed Commerce announces that Manon Brouillette has been re-appointed to its Board of Directors, effective October 1, 2023. This is Manon Brouillette's second term as one of Lightspeed's Board members.

08:29 EDT Urban-Gro awarded new contract worth $11M - Urban-Gro announced that the company was awarded a new contract with an existing client in the hospitality and recreation sector in the Southeast region of the United States. The contract scope includes architecture, design, engineering, and construction management services in the initial amount of more than $11M and will be predominantly realized over the next six quarters.

08:29 EDT Blink Charging announces agreement with Parkopedia - Blink Charging announced an agreement with Parkopedia, a leading global connected car and parking services provider, to integrate over 4,000 Blink EV charging locations onto the Parkopedia platform in North America. This strategic integration will grant the platform access to nearly 12,000 Blink public EV chargers, which includes 129 DC Fast Chargers. "Our collaboration with Parkopedia creates a streamlined experience for EV drivers to conveniently locate Blink EV charging stations across North America," said Jim Nemec, Chief Revenue Officer for Blink Charging. "The combination of Parkopedia's excellence in serving drivers through convenience in parking accessibility and Blink's extensive range of public EV chargers gives EV drivers confidence in finding a reliable charging experience wherever they are. This initiative builds upon our strategy of making it easy for EV drivers to locate Blink chargers through a variety of platforms."

08:28 EDT Biomerica announces Dubai gov approved insurance reimbursement for EZ Detect - Biomerica announced that the Dubai government, gov, has officially approved insurance reimbursement for the EZ Detect colorectal disease at-home screening test, which is designed to detect an early warning sign of colorectal cancer and other colorectal diseases. Colorectal cancer is the second most common cause of cancer death in the UAE.

08:27 EDT BlackBerry seleted by Mitsubishi for in-vehicle system - BlackBerry announced that Mitsubishi Electric's new automotive in-cabin system, Mitsubishi Electric FLEXConnect, will be powered by BlackBerry IVY, an edge-to-cloud vehicle data platform. BlackBerry IVY allows the platform to extract and analyze data from internal and external sensors and leverages machine learning to process all data collected at the vehicle edge compute node.

08:26 EDT Motus GI Holdings submits special 510k to FDA for Pure-Vu EVS - Motus GI Holdings announced that it has submitted a special 510(k) to the U.S. Food and Drug Administration for market clearance of its Pure-Vu Gen 4 Gastro and Colon. A special 510(k), according to FDA guidance, has an initial review usually within 30 days of receipt. The Pure-Vu EVS Gen 4 Gastro for upper gastrointestinal procedures and the improved version for the colon each provide significant benefits compared to previous Pure-Vu models and are designed to potentially open new segments of the GI market by introducing new capabilities while also addressing factors that make it easier to work with commercial partners. "The submission of this special 510(k) to the FDA brings us one step closer to being able to commercially launch our next generation system in the U.S. market. Expanding the Pure-Vu platform's capabilities into supporting upper GI procedures, an area of high unmet patient need, should accelerate the adoption of the Pure-Vu system in the market," commented Mark Pomeranz, Chief Executive Officer. "Our submission for 510(k) clearance of the Pure-Vu Gen 4 Gastro and Colon is supported by positive preclinical and clinical data collected by some of the top key opinion leaders in both the U.S. and abroad. These data show the value our new platform offers hospitals and patients suffering from a number of indications."

08:25 EDT Dick's Sporting to hire 8,600 seasonal teammates for holidays - Dick's Sporting Goods plans to hire 8,600 seasonal teammates for the 2023 holiday season. The sixth-annual "National Signing Day" on October 3 will kick off holiday recruiting efforts for positions at Dick's Sporting Goods, Public Lands, Dick's House of Sport, and Going, Going, Gone! stores across the country.

08:24 EDT Apollo Global marks one-year anniversary of Apollo Academy - Apollo marked the one-year anniversary of the launch of Apollo Academy, a knowledge center designed specifically for the financial-professional community. Launched in September 2022, Apollo Academy delivers a product-agnostic education ecosystem for advisors and intermediaries to learn about the role alternatives can play in individuals' portfolios and is an integral resource supporting the growth of Apollo's Global Wealth business. The Academy offers a full suite of learning modules on investing in alternatives, complete with continuing-education accreditation through live and on-demand events. It also features current investment intelligence from key experts at the firm, delivering markets and industry insights through white papers, articles, podcasts, the Daily Spark blog and more. Driven by the democratization of private market investments, the Academy exemplifies Apollo's efforts to create a purpose-built global wealth platform with resources to help investors and retirees learn about the potential benefits of alternatives in individuals' portfolios.

08:23 EDT Bone Biologics provides scientific update on NB1 bone graft device - Bone Biologics provides an update on its clinical development initiatives with its NB1 bone graft device. NB1 consists of the recombinant human protein NELL-1 combined with demineralized bone matrix . The 30-patient pilot study is expected to be conducted in Australia. Earlier this year, the Human Research Ethics Committee approved Monash Health as the first site. "We are encouraged by the ongoing progress in preparing to advance NB1 into human testing and look forward to the start of our pilot study before the end of the year," said Jeffrey Frelick, president and chief executive officer of Bone Biologics. The company has completed the following preparatory activities: Assay Qualification and Validation All analytical assays required for the drug substance and the drug product have been successfully validated. Similar recombinant human NELL-1 or rhNELL-1, drug substance attributes were demonstrated between different rhNELL-1 lots and the cGMP drug substance lot. The in vitro cell-based attachment potency assay has been successfully qualified. Similar relative potency was demonstrated between different rhNELL-1 lots and the cGMP drug substance lot has passed the potency specification. In vivo potency testing demonstrated osteopromotion activity for the cGMP rhNELL-1 drug substance. The engineering and the cGMP drug substance lots have passed all required specifications. Medical Device Biocompatibility Testing The ISO 10993 GLP biocompatibility testing has been completed. NB1 showed no evidence of causing cell lysis or toxicity, no sensitization and was not mutagenic or pyrogenic. The clinical observations, body weights, necropsy observations, organ weights, organ/body weight ratios and organ/brain weight ratios were not adversely affected.

08:21 EDT Heart Test Laboratories receives two new patent allowances - Heart Test Laboratories announced that it has been issued a notice of patent allowance from the Brazilian Patent and Trademark Office and the United Arab Emirates, UAE, Ministry of Economy, Intellectual Property Protection Department. These new patent awards increase HeartSciences' patent portfolio to now include 33 international granted or allowed patents and 9 US granted patents covering well over 100 claims. Andrew Simpson, Chief Executive Officer of HeartSciences, commented, "AI is now in daily use in healthcare and is expected to reinvent the ability of an ECG to screen for heart disease. We are pleased to further strengthen our extensive intellectual property portfolio as AI is expected to drive significant growth in the ECG market to $25 billion per year by 20321. HeartSciences is a leader in AI-based ECG technology being used in everyday clinical practice, and with the recent signing of agreements with Mount Sinai, a top-ranked hospital in cardiology, we expect to significantly expand our ECG cardiovascular disease screening capabilities."

08:20 EDT Candel Therapeutics reports initial survival data from Phase 2 trial of CAN-2409 - Candel Therapeutics announced updated activity data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor reatment in patients with non-resectable, stage III/IV non-small cell lung cancer, who have an inadequate response to front line anti-PD(L)1 therapy. These patients historically have had an expected median overall survival of 10-13 months. The aim of the CAN-2409 immunotherapy antitumor strategy is to raise the tail on the survival curve by increasing the number of long survivors beyond 10-13 months. In 2022, the Company presented data from this phase 2 clinical trial where patients who received two administrations of CAN-2409 plus prodrug demonstrated increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood, favorable changes in the trajectory of tumor progression, decreased tumor size of target lesions in most patients, and reduced size of uninjected tumor lesions. These data were further confirmed in the current update. Highlights as of August 1, 2023 data cutoff, include: As of data cutoff, 40 patients across Cohort 1 and Cohort 2 were evaluable, as they received two courses of CAN-2409 + valacyclovir and completed the 12-week treatment window. While overall survival is not yet mature, Candel has observed an encouraging number of long survivors, which the Company believes that CAN-2409 may induce a new state of functional immunosurveillance and durable disease control in a subset of the patients. Of the 40 evaluable patients, 15 patients have lived greater than or equal to 12 months; of these, 10 patients have lived greater than 18 months, of whom 70% were alive as of last follow up. All 4 patients with OS greater than 24 months were alive at last follow up, with the longest reaching 31.7 months. An additional 18 out of the 40 evaluable patients are also alive but have not yet reached 12 months of follow up. Notably, many patients treated with CAN-2409 have had long survival despite having disease features generally associated with advanced disease and reduced likelihood to benefit from ICI therapy, such as low or negative PD-L1 expression, including: Amongst patients alive greater than or equal to 12 months with known PD-L1 status, 93% had negative or low PD-L1 score. Advanced disease with stage IV in 73%, lymph node involvement in 73%, pleural effusion in 40%, bone metastases in 27%, adrenal metastases in 20%, brain metastases in 13%, liver metastases in 7%, involvement of 3 or more organs in 13%, and ECOG performance status 1 in 40%. There was a significant increase observed in activated central memory, effector-memory, effector T cells, and NK cells after CAN-2409 treatment. These include CD8+Ki67+IFNg+ T cells, CD8+ granzyme B+Ki67+ T cells, CD56+CD16+granzyme B+ NK cells, and gd+ T cells. Candel also observed an increase in B memory cells after CAN-2409 treatment. Candel observed an increase in effector/cytotoxic T cells and NK cells in peripheral blood after the second CAN-2409 administration associated with improved survival. Candel continued to observe a favorable safety / tolerability profile after CAN-2409 treatment in NSCLC. There were no dose limiting toxicities or grade 4 or greater treatment related adverse events. Grade 3 treatment related adverse events were reported in less than 10% of patients receiving at least one dose of CAN-2409, which Candel believes compares favorably to current standard of care options. Candel expects to share topline overall survival data for Cohort 2 in the second quarter of 2024, assuming mature data at that time.

08:19 EDT Bullfrog AI announces data from preclinical study on BF-222 - BullFrog AI announced positive data in a preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for the treatment of glioblastoma. The study assessed the relative efficacy of BF-222, a novel formulation of mebendazole that has been evaluated in clinical trials, and BF-223, a novel prodrug of mebendazole with improved solubility and bioavailability relative to BF-222, compared with placebo in mice that had been implanted with tumor cells as a model for human glioblastoma. Animals treated with BF-223 had an average survival time of 27.9 days compared with 27.3 days for mice treated with BF-222 and 23.4 days for mice given placebo. Mice treated with BF-223 were administered 80% of the dose that mice treated with BF-222 received, and improved outcomes for both treatment groups were statistically significant compared to placebo. In addition, animals treated with equivalent doses of BF-222 and BF-223 showed comparable and significant reduction in tumor growth compared to control animals during the study. Vin Singh, Chairman and CEO of BullFrog AI, said, "The data from this study, combined with BF-223's improved properties, gives us confidence that BF-223 has potential to be an effective treatment in the fight against glioblastoma, a form of cancer for which there are few good treatment options. We are currently pursuing partnering opportunities for BF-222 and BF-223 with pharmaceutical companies and are confident that these data will assist in that effort."

08:18 EDT Vaccinex reports findings at medical conferences on Pepinemab - Vaccinex will report on novel findings for its lead product, pepinemab, with implications for treatment of Alzheimer's and other slowly progressive neurodegenerative diseases and for cancer immunotherapy at two upcoming Medical Conferences. Results from phase 2 SIGNAL trial suggest pepinemab is the first therapeutic agent that appears to have the potential to prevent decline in brain metabolic activity and to slow or halt cognitive decline in Huntington's disease. Encouraged by these findings, a separate, randomized, phase 1/2a study in AD is ongoing in which the last patient is anticipated to complete the planned 12-months of treatment in early June 2024. Pepinemab in combination with a checkpoint inhibitor is, the first treatment that has shown the potential to induce formation of lymphoid structures in tumors that promote efficient immune responses and are known to be associated with improved outcomes in head and neck cancer. Clinical results indicate an approximate doubling of objective responses and progression free survival relative to historical results with checkpoint monotherapy in patients with hard-to-treat tumors that express low levels of PD-L1. Alzheimer's Disease: Vaccinex completed enrollment in the randomized, double-blind SIGNAL-AD phase 1/2a study for early AD in May 2023. The last patient is anticipated to complete the planned 12 months of treatment by early June 2024 at which time the database will be locked and results analyzed. Key endpoints include brain metabolic activity along with measures of cognition specific to AD. Clinical consensus is that Leqembi and donanemab provide a modest but real benefit to patients at a very early stage of disease. Common side effects associated with these drugs, however, include an inflammatory and hemorrhagic response in brain denoted as ARIA. "We believe that use of pepinemab to treat slowly progressive neurodegenerative diseases like AD has been substantially de-risked by results from our completed phase 2 study in HD,: the company said. Cancer: The Phase 2 KEYNOTE-B84 study evaluated Vaccinex's pepinemab antibody in combination with Merck's anti-PD-1 therapy, KEYTRUDA for immunotherapy of recurrent or metastatic head and neck squamous cell carcinoma. Results of a preplanned interim analysis of the first 36 patients treated in this study indicated that the Objective Response for the PD-L1 low population, CPS less than20, was 21.1% and median progression free survival was 5.79 months, which are approximately twice that of historical ORR and PFS for checkpoint monotherapy in this population. In contrast, in the CPS greater than or equal to20 subgroup, the ORR and PFS for combination therapy was similar to historical checkpoint monotherapy. The results indicate that treatment with pepinemab in combination with KEYTRUDA appears to induce formation of highly organized lymphoid aggregates in the tumor of patients who demonstrate disease control.

08:15 EDT Edgewise Therapeutics initiates enrollment of GRAND CANYON study - Edgewise Therapeutics announced the start of enrollment of GRAND CANYON, a global pivotal study of EDG-5506 in individuals with Becker. GRAND CANYON is an expansion of the CANYON study. CANYON, which was over-enrolled, includes 39 adults and 24 adolescents. EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Becker and Duchenne muscular dystrophy. There are currently no approved therapies for individuals with Becker, a serious genetic, progressive neuromuscular disorder with significant unmet need.

08:14 EDT Booz Allen announces investment in HiddenLayer, terms undisclosed - Booz Allen announced that its corporate venture capital arm, Booz Allen Ventures, has made a strategic investment in HiddenLayer, a security platform that safeguards machine learning, or ML, models. This investment strengthens and expands Booz Allen's tenured Adversarial AI capabilities, including those developed for the Department of Defense and intelligence clients, and will further accelerate secure adoption of enterprise AI solutions to keep pace with emerging national security threats as well as rising consumer expectations.

08:12 EDT Outbrain, DoubleVerify partner to enhance Onyx campaigns - Outbrain announced a strategic partnership to bring DV Marketplace Suite's comprehensive pre-bid brand suitability, fraud avoidance, and viewability tools to Outbrain's recently-launched branding platform, Onyx. "This partnership further demonstrates our commitment to delivering an exceptional advertising experience where advertisers can feel confident their Onyx campaigns only run in brand-suitable environments with verified and certified results by a globally-recognized third-party," said Ayal Steiner, EVP of Brand Solutions, Outbrain. "Our goal is to simplify the advertiser experience and deliver a seamless, turnkey solution, and this partnership is an important milestone in this direction."

08:12 EDT Surf Air Mobility confirms aircraft order & Textron deal for electric Cessna - Surf Air Mobility (SRFM) or SAM, "a regional air mobility platform aiming to sustainably connect the world's communities," confirmed its exclusive relationship with Textron Aviation (TXT) , upon the completion of its public market debut...the company announced that deliveries of the first 20 Cessna Grand Caravan EX aircraft are expected to begin in the first half of 2024. This exclusive relationship supports Surf Air Mobility's development of an electrified Cessna Grand Caravan EX, targeting FAA certification in 2026. Surf Air Mobility has agreed to purchase up to 150 Cessna Grand Caravan EX aircraft, with a confirmed initial fleet order of 100 aircraft and an option for 50 more. The aircraft will be upgraded to Surf Air Mobility's proprietary electric or hybrid-electric powertrain technology by Surf Air Mobility. Through this exclusive agreement, Surf Air Mobility plans to make electrified aircraft broadly available to new and existing operators, and to bring the benefits of lower cost, lower emission air travel at scale to customers. Surf Air Mobility will also be the exclusive provider to Textron Aviation of certain battery electric and hybrid electric powertrain technology for the Cessna Grand Caravan... "We are very proud of our relationship with Textron Aviation and excited to expand our growing network with this fleet order," said Jamie Strecker, head of Business Development for Surf Air Mobility. "This order brings us closer to our ultimate goal to electrify our entire fleet and bring the world a more sustainable way to fly." The aircraft should be immediately operable at more than 5,000 public use airports across the U.S. with no charging stations required for the hybrid-electric powertrain iterations ...Reducing the environmental impact of flying and paving the way for future generations of even more sustainable aircraft ..Opening the ability for more Cessna Grand Caravan owners and operators to upgrade to the electric or hybrid powertrains..

08:11 EDT QuickLogic awarded new eFPGA contract - QuickLogic has been selected by a technology company for an eFPGA IP targeting the GlobalFoundries 22FDX platform. The name of the customer cannot be disclosed at this time. QuickLogic's eFPGA solution, powered by the Australis IP generator, has been specifically chosen by the customer for its ability to create a customized version of its eFPGA IP within one quarter from contract signing.

08:10 EDT Phathom announces vonoprazan NDA submission for non-erosive GERD - Phathom Pharmaceuticals announced the submission of an NDA to the FDA for vonoprazan as a daily treatment for Non-Erosive gastroesophageal reflux disease, GERD, in adults. The regulatory submission is supported by the positive data from the PHALCON-NERD-301 study, a Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of adults with Non-Erosive GERD, NERD. Vonoprazan is an investigational first-in-class potassium-competitive acid blocker from a novel class of medicines that block acid secretion in the stomach. The effectiveness and safety of vonoprazan 10 mg and 20 mg given once daily in NERD was evaluated in a randomized, placebo-controlled, double-blind, 4-week trial with a 20-week blinded extension conducted in the United States in 772 adult patients. As previously reported, both vonoprazan doses met the primary endpoint for the mean percentage of heartburn free days over the 4-week placebo-controlled period at 45%, 44%, and 28% for vonoprazan 10 mg, vonoprazan 20 mg and placebo, respectively . As previously reported, the overall adverse events were comparable between vonoprazan and placebo during the 4-week placebo-controlled period of which the most common events were nausea, abdominal pain, constipation, and diarrhea, reported at or below 3% for either vonoprazan 10 mg or 20 mg doses. The most common adverse events reported for the two vonoprazan doses during the 20-week extension period were upper respiratory tract infection, sinusitis, influenza, urinary tract infection, nasopharyngitis, nausea, and gastroenteritis, reported at or below 5%. Phathom expects a 10-month regulatory review and if approved, anticipates a third quarter 2024 U.S. launch for vonoprazan as a daily treatment for Non-Erosive GERD. Phathom also plans to initiate an additional Phase 3 study to evaluate vonoprazan as an As Needed treatment for episodic heartburn relief in adults with Non-Erosive GERD, a novel dosing treatment regimen.

08:07 EDT GlobalFoundries announces annual Technology Summit in Europe - At its annual Technology Summit in Europe beginning September 27th, GlobalFoundries is highlighting key advancements to its technology platforms and solutions that will enable better power efficiency, enhanced performance and security for applications across critical end markets including IoT, smart mobile and automotive. These milestones highlight GF's semiconductor manufacturing leadership in product development, validation and market readiness for critical applications in IoT, 5G and 6G smartphones, and electric vehicles. Building upon the GF Technology Summit in North America this past August, the sessions in Munich will focus on leading at the edge, manufacturing semiconductors in a digital, AI-driven, world through the evolving landscape of communications infrastructure and the electrification of vehicles. GF's President and CEO, Dr. Thomas Caulfield, will kick-off the event with a keynote address entitled "Essential chips fuel the era of AI," which emphasizes the transformative potential of these technologies and their significance in the rapidly evolving semiconductor landscape. In addition, Peter Schiefer, Infineon Division President Automotive, Jean-Marc Chery, President and CEO of STMicroelectronics and Karsten Schnake, Board Member for Procurement at of KODA AUTO & Head of Project COMPASS at Volkswagen AG will take the stage.

08:07 EDT Akebia lowers 2023 Auryxia net product revenue guidance - Akebia slightly lowered Auryxia net product revenue guidance to $170M-$175M for 2023 from $175M-$180M due to an unfavorable impact from market dynamics, volume and payor mix.

08:06 EDT Akebia's Vafseo approved for anemia in Australia - Akebia announced that Australia's Therapeutic Goods Administration has granted approval for Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. Vadadustat achieved the primary and key secondary efficacy endpoint in each of the two INNO2VATE studies, demonstrating non-inferiority to darbepoetin alfa as measured by a mean change in hemoglobin between baseline and the primary evaluation period and secondary evaluation period. Vadadustat also achieved the primary safety endpoint of the INNO2VATE program. To support the global launch of Vafseo and prepare for a potential launch in the U.S., Akebia also announced an addition to its commercial team. Akebia appointed Graham Ray as VP, Key Accounts, reporting to Bennett Smith, Senior VP, Commercial, to lead customer engagement. Ray spent over nearly 20 years at Takeda Pharmaceuticals.

08:05 EDT Verizon announces upgrades from multi-year transformation of network - Verizon has recently undergone a major multi-year transformation of its network architecture to provide customers with more capabilities, upgrade the technology in the network, pave the way for personalized customer experiences and provide a platform for enterprises and developers to drive innovation. While this massive undertaking is not over, the results have been unmistakable, with customers using the network in more places in more ways and having a better experience on the Verizon network.

08:04 EDT electroCore expands IP portfolio for nVNS technology - electroCore announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices. U.S. Patent No. 11,766,562 entitled "Nerve Stimulator for Use with a Mobile Device" was issued on September 26, 2023, and is generally related to treating seizures, such as epileptic seizures that utilizes a system for transcutaneously stimulating a nerve within a patient whereby the system includes the stimulator and a mobile device that provides a wireless signal to enable the stimulator to operate.

08:02 EDT Azenta's CFO Lindon Robertson retiring, Herman Cueto succeeds - Azenta announced that Herman Cueto will join Azenta as Executive VP and CFO, effective October 16. Cueto, who comes from BD, will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Cueto joins Azenta from BD, which he joined in 2017 through its acquisition of CR Bard. Mr. Cueto most recently served at BD as Senior Vice President of Finance, overseeing Segments / Regions / BP&A / Operations. He formerly served as Senior Vice President and Chief Financial Officer of BD's Medical Segment. Prior, Cueto was at CR Bard for fourteen years, most recently as Vice President and Group CFO.

07:49 EDT Energy research association selects Draganfly Commander 3XL Platform - Draganfly announces a leading energy research association has chosen Draganfly's Commander 3XL Platform for inspection standards operations.

07:46 EDT Soleno announces statistically significant top-line results from Study C602 - Soleno Therapeutics announced positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR Extended-Release tablets for the treatment of Prader-Willi syndrome. Key Top-line Results: Hyperphagia-related behaviors markedly worsened in the placebo group compared to DCCR, represented by a highly statistically significant, clinically meaningful difference in mean change from baseline in the HQ-CT total score of 5.0 at week 16. Secondary endpoints of CGI-S and CGI-I both showed strong trends towards worsening in the placebo group compared to DCCR over the course of the randomized withdrawal period, respectively. DCCR continued to be generally well-tolerated in the randomized withdrawal period with no new or unexpected safety signals, including no serious adverse events or discontinuations due to adverse events occurring in any participants in the DCCR group.

07:43 EDT Mobile Global Esports concludes MOGO National Championship 2.0 - Mobile Global Esports produced the 'MOGO National Championship 2.0.' Following the virtual qualifiers, the championship event at Lovely Professional University in Phagwara, India, featured outstanding competitive play from 16 teams representing four geographic regions, marking a significant milestone in collegiate esports. MOGO produced the esports championship in cooperation with Elite Power Sports, which produced the national basketball, volleyball, and kabaddi university championships. The championship rounds featured upsets, underdog victories and thrilling overtime matches, including one match that lasted 38 rounds. The week-long live, LAN event showcased the remarkable skill and determination of the participating student teams. What set this event apart was the exceptional pro-level experience that MOGO provided to all the participating teams.

07:41 EDT Peraso receives initial EOL purchase orders totaling $11.3M - Peraso has received purchase orders from multiple customers totaling $11.3M. These non-cancelable orders represent last-time buys received to-date associated with the previously announced end-of-life program for the Company's memory integrated circuit products. Peraso has commenced fulfillment of these orders and expects shipments to extend through 2024.

07:40 EDT Small Pharma reports topline data from SPL026-SSRI drug interaction study - Small Pharma announces safety, tolerability and efficacy data from its Phase Ib study exploring the interaction between selective serotonin reuptake inhibitors and SPL026, native N, N-dimethyltryptamine, in patients with Major Depressive Disorder. The purpose of this study was to build upon the previously reported Phase I/IIa safety and efficacy profile of SPL026 with support therapy, to assess whether SPL026 can be safely administered with or without SSRIs - the current standard of care for MDD. In the Phase I/IIa SPL026 study, patients were required to be withdrawn from SSRIs, which can be a disruptive experience. Through the SPL026-SSRI drug interaction study, Small Pharma aimed to address this requirement, which could enable broader patient recruitment on future large-scale studies, and potentially accelerate the clinical development pathway. Additionally, removing the requirement to be withdrawn from SSRIs may facilitate patient access to SPL026 earlier in the MDD treatment journey, if approved. This open-label study investigated the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of a single 27.5 mg intravenous infusion of SPL026, alone or in combination with SSRIs, in 171 patients, together with support therapy. The test cohort consisted of patients currently on a stable treatment course of SSRIs, which have been ineffective in fully relieving their depression symptoms. The control cohort consisted of patients not currently using any pharmacological treatment to treat their depression symptoms. Patients were recruited with moderate-severe MDD as defined by a Hamilton Depression Rating Scale score of greater than14. Efficacy was assessed using the Montgomery-Asberg Depression Rating scale to measure any change in patients' depression symptoms from baseline. Additional exploratory endpoints include the Beck Depression Inventory to assess patients' self-reported depression. Safety & Tolerability: SPL026 was well-tolerated by all patients in both the SSRI Cohort and Non-SSRI Cohort, with no apparent differences between cohorts; No drug-related serious adverse events reported; A small number of drug-related adverse events reported: 8 in SSRI Cohort; 3 in Non-SSRI Cohort; All deemed to be mild or moderate in severity; Majority of drug-related AEs were resolved during the dosing visit. The results reaffirmed the efficacy initially demonstrated in the Phase IIa SPL026 study. However, a marked improvement was observed between the antidepressant effect of SPL026 treatment in the SSRI Cohort compared to the Non-SSRI Cohort. While the efficacy observed in the Non-SSRI Cohort was comparable to the efficacy data previously observed in the Company's SPL026 Phase IIa clinical trial, the antidepressant effects observed in the SSRI Cohort were of a greater magnitude, suggesting a potentially enhanced efficacy effect when SPL026 is administered in combination with SSRIs.

07:35 EDT Abeona Therapeutics submits BLA to FDA for EB-101 in RDEB - Abeona Therapeutics has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa. As part of the submission, Abeona requested a Priority Review, which, if granted, would shorten the FDA's review period to six months from the filing acceptance of the BLA, instead of 10 months under standard review. The BLA submission for EB-101 followed ongoing discussions with the FDA and is supported by clinical efficacy and safety data from the pivotal Phase 3 VIITAL study and confirmatory evidence from a Phase 1/2a study. Data from the VIITAL study were presented during the inaugural International Societies for Investigative Dermatology Meeting in May 2023. Long-term follow up data up to eight years and quality of life data from the Phase 1/2a study were published in Orphanet Journal of Rare Diseases. The FDA's decision on BLA acceptance is typically made during the 60-day window following submission. If accepted with Priority Review, Abeona expects potential BLA approval in the second quarter of 2024, at which time, Abeona believes that it would be eligible to receive a Priority Review Voucher. The voucher, if granted, could be used by the Company to accelerate the review of a future BLA or New Drug Application, or be sold to a third party. EB-101 has been granted Rare Pediatric Disease, Regenerative Medicine Advanced Therapy, Breakthrough Therapy and Orphan Drug designations.

07:33 EDT Cybin announces agreement with Fluence to support scaling of Embark training - Cybin announced an agreement with Fluence to support the streamlining and scaling of Cybin's Embark facilitator training program in preparation for a multi-site, global Phase 3 trial of CYB003, its proprietary deuterated psilocybin analog in development for the potential treatment of major depressive disorder, or MDD. This streamlined model of psychedelic facilitation training, known as Embark for Clinical Trials, is designed for individuals with existing experience, knowledge, and skills in psychedelic facilitation. Under the terms of the agreement, Fluence will support Cybin in the selection and training of facilitators for the planned Phase 3 trial. Fluence will also create supplemental video content and provide asynchronous and synchronous training in service of augmenting and verifying facilitator competencies.

07:30 EDT Manchester United up 4% after Bloomberg says Ratcliffe reworking buyout offer

07:19 EDT Liberty proposes combination with Sirius XM - Liberty (LSXMA) announced that it communicated a proposal to the special committee of the board of directors of Sirius XM (SIRI), which outlined the terms of a proposed combination of the Liberty SiriusXM tracking stock group with SiriusXM to form a new, consolidated public company. In the proposed transaction, Liberty would separate LSXM by means of a redemptive split-off of a newly formed subsidiary of Liberty, which would own all of the assets and liabilities attributed to LSXM. In the split-off, holders of each series of LSXM common stock would receive a number of shares of a single series of common stock of SplitCo calculated based upon each underlying share of SiriusXM common stock held by SplitCo being exchanged for 1.05 shares of common stock of New SiriusXM. SplitCo would then combine with SiriusXM to form New SiriusXM, with the minority shareholders of SiriusXM receiving shares in New SiriusXM on a one-for-one basis. In addition, the minority shareholders of SiriusXM would receive a pro rata cash payment calculated based on the amount of the outstanding net debt of LSXM effectively assumed by New SiriusXM in the proposed transaction. New SiriusXM would have a single outstanding series of common stock, with each share entitling the holder thereof to one vote per share. By way of example, based on recent outstanding share counts, holders of LSXM common stock would receive 10.3 shares of New SiriusXM common stock for each share of LSXM common stock held at closing, and, based on the projected outstanding principal amount of LSXM net debt at year end, the minority shareholders of SiriusXM would receive one share of New SiriusXM common stock plus 55c in cash for each share of SiriusXM common stock held at closing. The minority shareholders of SiriusXM would collectively own approximately 16% of New SiriusXM, and the former holders of LSXM common stock would collectively own approximately 84% of New SiriusXM. The proposed transaction is intended to be tax-free and would be subject to, among other things, the negotiation and execution of mutually acceptable definitive transaction documents and applicable board approvals, including the approval of a Special Committee. No further updates on the proposed transaction will be provided unless and until definitive documents are executed or discussions between the parties terminate. The proposed transaction would not result in any changes to the Liberty Formula One tracking stock group or the Liberty Live tracking stock group.

07:15 EDT Liberty Media proposes to combine Liberty SiriusXM with Sirius XM - In a regulatory filing, Liberty Media disclosed that on September 22, Liberty Media communicated a proposal to the Special Committee of the Board of Directors of Sirius XM (SIRI) which outlined the terms of a proposed combination of Liberty Media's Liberty SiriusXM tracking stock group (LSXMA) with Sirius XM to form a new, consolidated public company. "In the proposed Combination, the Reporting Person would separate LSXM by means of a redemptive split-off of a newly formed subsidiary of Liberty, 'SplitCo,' which would own all of the assets and liabilities then attributed to LSXM. In the Split-Off, holders of each series of LSXM common stock would receive a number of shares of a single series of common stock of SplitCo calculated based upon each underlying share of Common Stock held by SplitCo being exchanged for 1.05 shares of New SiriusXM common stock. SplitCo would then combine with the Issuer to form New SiriusXM, with the minority shareholders of the Issuer receiving shares in New SiriusXM on a one-for-one basis. In addition, the minority shareholders of the Issuer would receive a pro rata cash payment calculated based on the amount of the outstanding net debt of LSXM effectively assumed by New SiriusXM in the proposed transaction. New SiriusXM would have a single outstanding series of common stock, with each share entitling the holder thereof to one vote per share. By way of example, based on recent outstanding share counts, holders of LSXM common stock would receive 10.3 shares of New SiriusXM common stock for each share of LSXM common stock held at closing, and, based on the projected outstanding principal amount of LSXM net debt at year end, the minority shareholders of the Issuer would receive 1 share of New SiriusXM common stock plus $0.55 in cash for each share of Common Stock held at closing. The minority shareholders of the Issuer would collectively own approximately 16% of New SiriusXM, and the former holders of LSXM common stock would collectively own approximately 84% of New SiriusXM. The Combination is intended to be tax-free, except with respect to any cash received, and would be subject to, among other things, the negotiation and execution of mutually acceptable definitive transaction documents and applicable board approvals, including the approval of a Special Committee. No further updates on the Proposal or the proposed Combination will be provided unless and until definitive documents are executed or discussions between the parties terminate, or unless otherwise required by applicable law," the filing stated. Reference Link

07:12 EDT Amwell and HealthGorilla announce new lab capability with Converge platform - Health Gorilla and interoperability solution provider Amwell announce a new lab capability within the Amwell Converge virtual care platform. Providers practicing on the Converge platform will be able to offer patients a more connected hybrid care experience through streamlined lab processes, enhanced digital diagnostic data capabilities, and access to a broader nationwide lab network. An individual's medical journey is highly dependent on diagnostic lab results. Up to 70% of clinical decisions are influenced by laboratory results1 and approximately 30% of patient encounters result in a provider ordering a lab test..."Health Gorilla's lab automation system is leveraged by leading provider organizations to automate their clinical workflows, and we're thrilled to add Amwell as our newest collaborator," said Steve Yaskin, chief executive officer at Health Gorilla. "Labs are a critical variable in the patient's care journey, and we're proud to empower providers using the Amwell Converge platform with more access to diagnostic data."

07:11 EDT Lifeist Wellness' Mikra introduces new mental health product - Lifeist Wellness provided a corporate update for its U.S. biosciences subsidiary Mikra Cellular Sciences including the development of a new and proprietary supplement aimed at supporting the mental health issue of anxiety. "We are pleased to share an update on the continued progress of our U.S. biosciences subsidiary, Mikra Cellular Sciences Inc.," said Meni Morim, CEO of Lifeist. "Mikra's mission is to enhance vigorous lifespan and well-being by focusing on cellular health. Toward that goal, we have developed a new supplement to help support mental wellness, a pressing global concern. We are building off the success of our flagship product, CELLF which utilizes bioactive compounds to impact various bodily systems, reflecting our commitment to evidence-backed innovation. CELLF's availability on Amazon marks a significant expansion of distribution channels, with initial sales showing promising growth. We look forward to sharing more details about our new mental health product as we work to finalize the lab formulation in the 4th quarter." After the launch of CELLF and its improved version CELLF v1.2, a cellular health nutraceutical gel formulated with bioactive compounds to positively impact your brain, heart, skin and muscular systems, Mikra is dedicated to unveiling innovative products that add healthy, active, and high-quality years to one's life. It is currently in the formulation finalization phase of achieving a proprietary supplement aimed at supporting mental health among those who wrestle with anxiety. This initiative is in direct response to the growing worldwide emphasis on mental well-being and the "quiet epidemic" of anxiety among young adults, caused by the unprecedented pressures of life in the 21st century which have brought mental health to the forefront.1 Mikra is committed to leading the way in exploring natural supplements to help support our customers in their journey, without the adverse side effects of harsh and habit-forming pharmaceutical interventions.

07:09 EDT American Lithium announces new lithium discovery near Quelcaya - American Lithium announces a new lithium discovery from the initial drill hole completed at one of the key discovery targets previously identified from 2021 field work conducted near the Community of Quelcaya. Simon Clarke, CEO of American Lithium, states, "We are very excited with this discovery drill hole at Quelcaya. The lithium mineralization is in rocks that are texturally and geologically distinct from the Falchani tuff mineralization, but are obviously related to the same 8-million-year-old volcanic activity responsible for Falchani. The potential scale of this area of lithium mineralization is very large given the thickness seen in the discovery hole. The potential to pre-concentrate the lithium in this style of mineralization is also very encouraging as we start to analyze the leachability and economic potential. This discovery also validates our thesis that the Macusani Plateau hosts more than just the Falchani lithium deposit and has the potential to become a major lithium district, which we control."

07:08 EDT Avalo Therapeutics eliminates $35M debt - Avalo Therapeutics (AVTX) announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation (HRZN). This significant milestone not only signifies the company's steadfast commitment to financial stability but also paves the way for future accelerated growth and progress toward executing its ambitious plans to advance its most promising drug candidates, including its anti-LIGHT mAb and its BTLA agonist fusion protein

07:07 EDT AN2 Therapeutics geta Bill & Melinda Gates Foundation grant for TB & Malaria - AN2 Therapeutics announced that it has received a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis and malaria. Funding from the Gates Foundation will support the discovery of novel inhibitors of aminoacyl-tRNA synthetases using AN2's proprietary boron chemistry platform. AN2's boron chemistry has the potential to address biological targets for tuberculosis and malaria that build on the scientific expertise of several AN2 scientists that were involved in discovering novel leucyl-tRNA synthetase inhibitors including epetraborole, tavaborole, as well as ganfeborole, which is currently in development for tuberculosis. AN2's boron chemistry platform has demonstrated success against leucyl- tRNA synthetase, a target that has proven difficult to inhibit using traditional medicinal chemistry approaches. " ...This grant underscores our commitment to address areas of high unmet need in global health and capture synergies with our existing research programs using non-dilutive funding."

07:06 EDT Omega Therapeutics announces preliminary clinical data for OTX-2002 - Omega Therapeutics announced encouraging preliminary safety, tolerability, pharmacokinetic and translational data from the initial two dose level cohorts from Part 1 of its ongoing Phase 1/2 MYCHELANGELO I study evaluating OTX-2002 in patients with hepatocellular carcinoma and other solid tumors associated with the c-MYC gene. Key Highlights: Translational: Highly specific on-target engagement and intended epigenetic changes at the target genomic loci were observed for all eight patients across both dose levels, as evidenced by a robust increase in cell-free DNA MYC methylation signal following administration with OTX-2002. The increased methylation signal persisted throughout the two-week dosing interval. Epigenetic modulation of MYC translated to rapid, robust and durable downregulation of MYC expression in all eight patients, with mean reductions across both dose levels of approximately 55% observed 7 days following administration with OTX-2002. The increase in methylation and corresponding downregulation of MYC expression observed clinically are within the ranges that led to anti-tumor activity in preclinical xenograft models. Pharmacokinetics: Consistent pharmacokinetic data across both dose levels with rapid clearance and minimal variability observed within and between patients. No accumulation was observed following repeat administration, and low, transient levels of immune response were observed with no related adverse events or impact on PK observed. Both initial dose levels are below the predicted threshold for anti-tumor activity based on preclinical models. Safety and Tolerability: At both dose levels, OTX-2002 was generally well tolerated, with no dose-limiting toxicities.The majority of adverse events observed in the trial were grade 1 or 2. The most common treatment-related adverse events were infusion-related reactions including fever and chills, generally consistent with the known profile of other FDA-approved LNP-delivered therapeutics.

07:04 EDT Amwell, Health Gorilla announce expanded digital diagnostic lab ordering - Health Gorilla and Amwell announce a new lab capability within the Amwell Converge virtual care platform. Providers practicing on the Converge platform will be able to offer patients a more connected hybrid care experience through streamlined lab processes, enhanced digital diagnostic data capabilities, and access to a broader nationwide lab network.

07:03 EDT Ionis Pharmaceuticals' olezarsen meets primary Phase 3 efficacy endpoint - Ionis Pharmaceuticals announced positive topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome - FCS -. The trial met its primary efficacy endpoint with a statistically significant reduction in triglyceride levels with the olezarsen 80 mg monthly dose at six months compared to placebo; triglyceride lowering continued to improve at 12 months. In addition, olezarsen 80 mg showed a 100% reduction in acute pancreatitis events compared to placebo, a key secondary endpoint. Treatment with olezarsen 80 mg resulted in a greater than75% reduction in apoC-III, a protein produced in the liver that regulates TG metabolism in the blood. Olezarsen demonstrated a dose-dependent effect, with both study doses showing a substantial reduction in pancreatitis. The lower 50 mg dose did not reach statistical significance at six months on the primary endpoint of triglyceride lowering. Ionis plans to file a New Drug Application in early 2024 with the FDA in addition to EU regulatory filings. If approved, olezarsen would be the first available treatment in the U.S. for FCS, a rare, debilitating genetic disease that can lead to acute, potentially fatal pancreatitis attacks. The FDA granted olezarsen Fast Track designation for the treatment of FCS in 2023. Olezarsen demonstrated a favorable safety and tolerability profile in the study. There were more adverse events in the placebo group compared to the olezarsen groups, primarily due to pancreatitis events.

07:02 EDT GreenPower Motor reports results from EV school bus pilot program in W. Virginia - GreenPower Motor recently announced the results from its successful all-electric school bus pilot program conducted in West Virginia that resulted in subsequent all-electric school bus orders. GreenPower shared its findings along with helpful data to improve future deployments at the Green Bus Summit held during STN EXPO in Reno, Nevada this summer. "The GreenPower all-electric school buses did what they were supposed to do throughout the entire pilot. The buses transported the kids to school in the morning, home safely at night, and in some cases, on to football games or other extracurricular activities," GreenPower Vice President of Business Development and Strategy Mark Nestlen said in releasing the program results. "There was no case where the buses failed to perform nor meet the demands of the school districts and drivers." As a result of the successful pilot program and the performance of the GreenPower vehicles, schools in the Mountain State have placed orders to purchase GreenPower all-electric, purpose-built school buses to deploy in their fleets, and have also asked to receive GreenPower school buses purchased by the state. Several of the pilot program counties have applied for new funding through the EPA and other sources to purchase additional GreenPower school buses as well.

06:59 EDT Bausch + Lomb launches LUMIFY EYE ILLUMINATIONS in U.S. - Bausch + Lomb announced the U.S. launch of LUMIFY EYE ILLUMINATIONS, a new line of hypoallergenic specialty eye care products scientifically developed to cleanse, nourish and brighten the sensitive eye area.

06:57 EDT United Natural Foods appoints three new independent directors to board - United Natural Foods announced the addition of three new members to its Board of Directors as part of the company's ongoing customer and supplier focused transformation plan and commitment to strong corporate governance and shareholder value creation. Effective September 28, 2023, Lynn Blake, James "Jim" Loree and James Pappas will join UNFI's Board as new independent directors. In addition, in connection with a Cooperation Agreement UNFI entered with JCP, the Board will also oversee a financial review designed to enhance the company's performance and drive shareholder value creation. Both actions are aimed at accelerating UNFI's transformation and positioning the company for both near- and long-term success.

06:51 EDT NYSE to start delisting proceedings against Sunlight Financial - The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the securities of Sunlight Financial Holdings from the NYSE. Trading in the company's securities will be suspended immediately. "NYSE Regulation reached its decision to delist the company's securities pursuant to Section 802.01B of the NYSE's Listed Company Manual because the company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the securities upon completion of all applicable procedures, including any appeal by the company of the NYSE Regulation staff's decision," the exchange stated. Reference Link

06:45 EDT Trimble, Kyivstar partner to install new CORS network - Trimble and Kyivstar are partnering to install a new Continuously Operating Reference Station, or CORS, network to provide Global Navigation Satellite System, or GNSS, correction services across the country. Available to users as an annual subscription service, the new network will be built using Trimble's hardware and software positioning technology.

06:33 EDT Ault Inc. to acquire majority stake in Eco Pack Technologies - Ault Alliance's wholly owned subsidiary, Eco Pack Technologies, Inc., has entered into an agreement to acquire an 80% ownership stake in Eco Pack Technologies LTD. Eco Pack offers eco-centric packaging alternatives. Using digital technology enabling data driven analysis and decision making, Eco Pack develops packaging that marries sustainability with reduced environmental repercussions. Eco Pack's solutions are poised to replace conventional cardboard boxes and shrink-wraps prevalent in major retail chains. The closing of the agreement remains subject to the parties thereto meeting customary closing conditions and obtaining regulatory approval.

06:31 EDT Fisker expects to ramp deliveries to 300 vehicles per day later this year - Fisker announced that it has built 5,000 Fisker Ocean SUVs and expects to ramp deliveries of the Ocean to 300 vehicle per day later this year. To date, Fisker has delivered over 900 customer vehicles in its European and US launch markets. Several hundred more are expected to be delivered this week.

06:19 EDT Infosys, Microsoft to jointly develop AI solutions - Infosys (INFY) announced that it is collaborating with Microsoft (MSFT) to jointly develop solutions that leverage Infosys Topaz, Azure OpenAI Service and Azure Cognitive Services. Both organizations are bringing together their respective artificial intelligence, or AI, capabilities in an effort to enhance enterprise functions with AI-enabled solutions across multiple industries. Through the collaboration with Microsoft, Infosys Topaz is using Azure OpenAI Service and Azure Cognitive Services to augment its capabilities, in order to help enterprise customers transition from digital to AI solutions.

06:05 EDT Socket Mobile adds upgrade option to free barcode scanner on iOS - Socket Mobile announced it is now possible to upgrade from its free SocketCam C820 to the SocketCam C860 , an enhanced camera-based barcode scanner for iOS.

06:04 EDT Ideaya Biosciences granted Fast Track designation for IDE161 program by FDA - Ideaya Biosciences announced that the FDA has granted Fast Track designation to Ideaya's development program investigating IDE161, a potent and selective inhibitor of poly glycohydrolase, for the treatment of adult patients having advanced or metastatic ovarian cancer with germline or somatic BRCA 1/2 mutations who are platinum resistant and have received prior antiangiogenic and poly polymerase inhibitor therapies.

05:37 EDT Alibaba intends to spin-off Cainiao by way of separate listing - Alibaba announced that the company intends to spin-off Cainiao by way of a separate listing of the Cainiao Shares on the Main Board of the Hong Kong Stock Exchange. The company submitted a spin-off proposal to the Hong Kong Stock Exchange and the exchange has confirmed that the company may proceed with the proposed spin-off, Alibaba said in a statement. Upon completion of the spin-off, the company will continue to hold more than 50% of the shareholdings in Cainiao and therefore Cainiao will remain as a subsidiary of Alibaba.

05:07 EDT Clarivate creates Academia & Government Innovation Incubator, acquires Alethea - Clarivate announced it has established an Academia & Government Innovation Incubator. The Incubator's first program focuses on realizing better learning outcomes and student success through the acquisition of Alethea, an AI-powered students' content engagement platform created by Pangea. Alethea facilitates engagement with academic texts, class readings, and assignments through personalized and adaptive guidance.